Key Highlights
- Compass Pathways stock climbed +30.18% during pre-market hours, hitting $13.50
- First quarter adjusted EPS of -$0.30 exceeded analyst forecasts of -$0.43
- FDA approved rolling NDA submission process for COMP360 psilocybin treatment
- Company secured Commissioner’s National Priority Voucher, which could accelerate review by 1-2 months
- Several Wall Street firms increased price targets, with consensus rating of “Strong Buy” from 11 analysts
Compass Pathways started the week with momentum. The UK-based biotechnology firm saw its shares surge over 30% in pre-market activity on Monday, climbing to $13.50 — surpassing its previous 52-week peak of $11.28.
The dramatic price action stemmed from a convergence of three positive developments: stronger-than-expected quarterly results, a significant regulatory advancement, and a coveted federal voucher.
Regarding financial performance, Compass posted first quarter adjusted earnings per share of -$0.30, outperforming Wall Street’s consensus forecast of -$0.43. While still representing a loss, such outperformance carries weight for clinical-stage biotechnology companies.
The more substantial development emerged on the regulatory side. The FDA authorized Compass to proceed with a rolling New Drug Application submission and review process for COMP360, the company’s synthetic psilocybin therapy designed for treatment-resistant depression. This process has already commenced.
Additionally, Compass was awarded a Commissioner’s National Priority Voucher. This special designation has the potential to reduce FDA review periods by one to two months — a significant advantage when approaching commercialization.
The company has already filed at least one of three required NDA modules. Complete submission remains on track for the fourth quarter of 2026, with commercial readiness anticipated by year’s end.
Wall Street Responds Positively
Analyst firms moved swiftly. TD Cowen maintained its Buy recommendation. RBC Capital upgraded its price target from $21 to $22 while keeping its Outperform stance, pointing to supportive regulatory conditions and robust clinical data. Maxim Group made the most aggressive adjustment, raising its target from $12 to $20. Morgan Stanley increased its projection from $16 to $17 while maintaining an Overweight rating.
Among 11 covering analysts, the consensus recommendation for CMPS stands at “Strong Buy.”
The regulatory environment received additional support from a White House executive directive instructing the DEA to expedite rescheduling assessments for psychedelic compounds that have successfully completed Phase 3 clinical trials. Current regulatory framework allows DEA rescheduling reviews to proceed simultaneously with FDA evaluations.
Compass anticipates COMP360 will first be reclassified as Schedule 2, with final rescheduling possibly occurring within days of FDA approval — a timeline that eliminates some regulatory ambiguity that has previously impacted the psychedelic therapeutics sector.
Upcoming Milestones for COMP360
Data from Part B of the COMP006 Phase 3 clinical trial is anticipated in early third quarter 2026. This data release will attract significant attention from investors and industry observers.
The company closed the quarter holding $466 million in cash and cash equivalents, providing operational funding through 2028. This financial cushion eliminates immediate concerns about additional capital raises.
It’s noteworthy that broader equity markets experienced declines on Monday — both the S&P 500 and Nasdaq finished lower. The CMPS rally occurred independently of market trends.
The biotechnology firm is also slated to present at an approaching investor conference, which could maintain visibility among institutional investment managers in coming weeks.
